Abstract Released for E7386, Created Through
Collaborative Research Between Eisai and PRISM
TOKYO, Sept. 8,
2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd.
("PRISM"), a leading discovery and development biotechnology
company designing small molecule inhibitors of protein-protein
interaction (PPI) targets, today announced that the interim
analysis of a combination study of E7386(*1), created through
collaboration research with Eisai Co., Ltd. ("Eisai"), and
Lenvatinib mesylate ( "lenvatinib") (*2) will be presented by Eisai
at the European Society for Medical Oncology (ESMO) Congress 2024,
held in Barcelona, Spain from
September 13 to 17, 2024. The
abstract of the study has been released today.
To determine the recommended dose of E7386 in combination with
Lenvatinib in the open-label Phase Ib study(NCT0400879(*3)),
expansion cohort of advanced endometrial cancer patients progressed
following platinum-based chemotherapy and anti-PD-(L)1
immunotherapy have been implemented by Eisai. By data cutoff
(Mar 7, 2024) in 16 patients,
31% (5 patients) showed the confirmed partial response (decrease of
tumor size > 30%), and 31% (5 patients) showed the
stable disease (tumor size -30% to +20%).
These results confirmed promising preliminary antitumor activity
of E7386 + Lenvatinib with a manageable safety profile. To complete
the study, enrollment to the expansion part is ongoing.
(*1) E7386
E7386 is an orally available small molecule CBP/ β-catenin
inhibitor that inhibits protein-protein interactions between the
transcription factor CBP and β-catenin, and regulates the Wnt
signaling. E7386 achieved clinical POC (Proof of concept) in
October 2021 and following clinical
studies are ongoing including phase I for solid tumors as
monotherapy, Phase Ib for solid tumors in combination with tyrosine
kinase inhibitor Lenvatinib, Phase Ib/II for solid tumors in
combination with pembrolizumab, the anti-PD-1 antibody from Merck
& Co., Inc., Rahway, NJ,
USA.
(*2) Lenvatinib
Lenvatinib is a multi-kinase inhibitor, discovered by Eisai and
being co-developed and co-commercialized under a collaboration
agreement with Merck & Co., Inc., Rahway, NJ, USA, which inhibits vascular
endothelial growth factor receptors (VEGFRs),VEGFR1, VEGR2, VEGFR3
and fibroblast growth factor receptors (FGFRs), FGFR1, FGFR2,
FGFR3, FGFR4, and other receptor tyrosine kinases, PDGFR-alpha,
KIT, RET. Lenvatinib have been approved for thyroid cancer,
hepatocellular carcinoma, thymic caner and renal cell carcinoma (in
combination with Everolimus or pembrolizumab, the anti-PD-1
antibody from Merck & Co., Inc., Rahway, NJ, USA.). Lenvatinib is also approved
for endometrium cancer in combination with pembrolizumab
(*3) NCT04008797
NCT04008797 is an open-label Phase Ib study of E7386 in
combination with other anticancer drug, Lenvatinib for the patients
with solid tumors. The study has been implemented by Eisai in
Japan, Korea, Taiwan, US, and
France determine the safety
and the recommended phase 2 dose (RP2D) and also to see the
pharmacokinetics and efficacy of E7386 + Lenvatinib. Enrolment of
each cohort of hepatic, colon, endometrial cancers are ongoing.
About PRISM BioLab
PRISM BioLab is a discovery and development biotechnology
company utilizing proprietary PepMetics® technology to discover
orally available small molecule inhibitors of protein-protein
interaction (PPI) targets and transform lives of patients suffering
from cancer, autoimmune, fibrosis and other diseases. PepMetics®
are a unique class of small molecules that mimic three-dimensional
structures of alpha-helix and beta-turn, the peptide structures
commonly found in intracellular PPI interphases and receptor-ligand
interactions. By combining proprietary chemistry, know-how around
PPI targets and AI-supported design, PepMetics® technology can
deliver inhibitors of challenging PPI targets. The technology holds
promise to expand the field of drug discovery by turning previously
undruggable PPIs into targets readily druggable with small
molecules and by generating oral small molecule alternatives for
injectable biologics.
PRISM BioLab is collaborating on new PPI targets with global and
Japanese pharmaceutical companies. PepMetics® targeting
CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara
Pharmaceuticals Co., Ltd. are in clinical development for cancer
and liver disease, respectively.
www.prismbiolab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eisai-to-present-e7386-co-created-by-prism-biolab-and-eisai-at-the-esmo-european-society-for-medical-oncology-annual-meeting-302241213.html
SOURCE PRISM BioLab Co., Ltd.